MabCure Stock

MabCure ROA

The Return on Assets (ROA) of MabCure (MBCI) as of Aug 14, 2026 is -254.92 %.

ROA

-254.92 %

Last updated:

In 2026, MabCure's return on assets (ROA) was -254.92 %, a % increase from the - ROA in the previous year.

Access this data via the Eulerpool API

MabCure Stock analysis

What does MabCure do? MabCure Inc is a company that focuses on the development of novel antibodies for the treatment of diseases. The company was founded in 2016 and is based in San Francisco. The founders of MabCure gathered their expertise in biotechnology and pharmaceutical companies before starting the firm. MabCure's business model includes the identification of therapeutic antibodies using innovative technologies. The company utilizes a platform developed by them to produce antibodies in a fast and cost-effective manner. MabCure has a broad patent portfolio and has the capability to license its technology to other companies. MabCure operates in different fields, with the main ones being oncology, neurology, and immunology. In oncology, the company focuses on the development of antibodies against cancers such as breast cancer, prostate cancer, and lung cancer. In neurology, MabCure conducts research on antibodies that can be used in diseases such as Alzheimer's, Parkinson's, and stroke. In immunology, the company develops antibodies that can support the immune system in autoimmune diseases such as lupus and rheumatoid arthritis. MabCure has several products in the pipeline tailored to the different fields. One of the most promising products is an antibody targeting the protein PD-L1. PD-L1 plays a crucial role in preventing the immune system's defense response against cancer cells. The MabCure antibody against PD-L1 has already been tested in clinical trials and has shown promising results. Another promising product is an antibody against a protein called tau, which accumulates in the brains of Alzheimer's patients. The MabCure antibody against tau is currently in preclinical development. MabCure collaborates closely with academic institutions and other companies to advance its technologies and products. The company has partnerships with leading pharmaceutical companies such as Merck and Pfizer to license and market its technologies. MabCure also has partnerships with academic institutions such as the University of California, San Francisco and Stanford University to conduct joint research projects. Overall, MabCure is a promising company that focuses on the development of novel antibodies for the treatment of diseases. The company has strong scientific expertise and utilizes innovative technologies to develop its products. Through its partnerships with other companies and academic institutions, MabCure is able to market and sell its technologies and products on a broad scale. MabCure is one of the most popular companies on Eulerpool.

ROA Details

Understanding MabCure's Return on Assets (ROA)

MabCure's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing MabCure's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider MabCure's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in MabCure’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about MabCure stock

Return on Assets (ROA) of MabCure is -254.92 % in 2026.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) MabCure since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s MabCure with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — MabCure

All Key Metrics — MabCure